Trial reportBMC medicine2026
Efficacy and safety of albendazole versus praziquantel in the treatment of Clonorchis sinensis infection: an infection intensity-stratified, open-label, phase 2, randomized controlled trial.
Trial report in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPraziquantel is the only drug recommended against Clonorchis sinensis, while adverse events are usually high. Albendazole is documented in treatment of clonorchiasis, but the evidence is low due to lack of high-quality randomized controlled trials.
methodsWe did an exploratory randomized controlled trial in Binyang county, Guangxi, China. Eligible participants were adults aged 18-70 years with C. sinensis infection. Patients with light intensity (eggs per gram of feces (EPG): 1-999) and moderate plus heavy intensity (EPG: ≥ 1000) were randomly assigned to treatment groups respectively, with block sizes of two, four, and six, to receive praziquantel (25 mg/kg three times a day for 1 day) or albendazole (400 mg twice a day for 4 days) in a 1:1 ratio. Laboratory diagnosis technicians were blinded to group assignment. We assessed efficacy as cure rate and egg reduction rate in available-case analysis, while adverse events were also analyzed.
resultsFifty-two patients with light intensity and 50 with moderate plus heavy intensity were assigned, when three were lost to follow-up. The cure rate was 84.0% (21/25, 95% confidential intervals: 63.9%-95.5%) using praziquantel and 30.8% (8/26, 14.3%-51.8%) using albendazole in light intensity stratum (χ²=14.7, p < 0.001). It was 60.9% (14/23, 38.5%-80.3%) using praziquantel and 8.0% (2/25, 1.0%-26.0%) using albendazole in moderate plus heavy intensity stratum (χ²=15.1, p < 0.001). The corresponding egg reduction rate using geometric mean of EPG was 99.9% (99.7%-100.0%), 97.1% (94.1%-98.8%), 100.0% (99.9%-100.0%), and 98.9% (97.8%-99.5%), respectively. The overall cure rate was 72.9% (35/48, 58.2%-84.7%) in praziquantel groups and 19.6% (10/51, 9.8%-33.1%) in albendazole groups (χ²=28.3, p < 0.001), while the corresponding egg reduction rate was 99.9% (99.8%-100.0%) and 98.3% (97.1%-99.1%). The proportion of adverse events was higher in praziquantel than albendazole in light intensity stratum (46.2% vs. 15.4%), while there was no difference in moderate plus heavy intensity stratum (20% vs. 20%). The overall proportion was 33.3% in praziquantel groups and 17.6% in albendazole groups.
conclusionsAlbendazole (400 mg twice a day for 4 days) demonstrates high egg reduction rate and low adverse events, but low cure rate in C. sinensis infection. Its application in preventive chemotherapy for morbidity control deserves further exploration.
trial registrationControlled-Trials.com, ISRCTN46268871.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.